They treat different parts of the same knee

Both names appear in the same search results, on the same clinic pages, and sometimes in the same conversation — so it is easy to assume ChondroFiller® and Arthrosamid® are two versions of the same treatment, priced similarly and doing much the same job. They are not. They work on different structures inside the knee, and for most patients the question is not which one to choose, but whether one, the other, or both apply to their specific joint.

ChondroFiller® is an injectable Type I collagen scaffold. Placed under ultrasound guidance into a focal defect on the load-bearing cartilage surface, it gels in place within a few minutes and then recruits the patient's own progenitor cells to remodel the scaffold into cartilage-like tissue — a process known as acellular matrix-induced chondrogenesis that unfolds over roughly six to twelve months.

Arthrosamid® works somewhere else entirely. It is a 2.5% cross-linked polyacrylamide hydrogel — 97.5% water — injected into the joint as a single outpatient procedure. Over ten to fourteen days it integrates sub-synovially, lining the inner wall of the joint capsule and acting as a permanent mechanical cushion for the synovial membrane. It does not regenerate cartilage.

The practical upshot: ChondroFiller® addresses the cartilage surface at the bone ends; Arthrosamid® addresses the joint lining. Neither is universally superior — the right choice depends on what an MRI actually shows, not on patient preference. The sections that follow cover who each treatment suits, what the published evidence says about outcomes, and how both are delivered.

Which patients are suitable for each treatment

The scan determines the pathway — not the pain score, the patient's age in isolation, or anything they have read about either product.

The archetypal ChondroFiller® candidate

ChondroFiller® is suited to younger-to-middle-aged adults who have a focal, well-defined Grade III or IV cartilage defect — most often the result of a sports injury or trauma — set within an otherwise healthy joint. The surrounding cartilage should be largely intact, because the scaffold relies on good-quality neighbouring tissue and viable progenitor cells migrating in from the subchondral bone and synovium. Widespread, end-stage joint degeneration is not the right context for this treatment.

The archetypal Arthrosamid® candidate

Arthrosamid® is designed for a different clinical picture: diffuse osteoarthritis — including Kellgren-Lawrence Grade III or IV — where the dominant presentation is chronic pain, joint swelling, and a reactive, inflamed synovial lining. Patients in this group often describe pain at rest or overnight, regular flares, and a joint that feels persistently irritable rather than one with a specific injury site. The hydrogel targets that synovial environment, not a discrete surface defect.

Why self-selection is unreliable

The distinction matters because neither treatment is a catch-all. A patient with diffuse wear would gain little from a scaffold placed over a focal defect that does not exist; a patient with a discrete chondral lesion would not be treated by cushioning the joint lining alone. Where MRI shows both surface cartilage loss and synovial inflammation, a combination approach may be relevant — that is covered in a later section. The right pathway emerges from imaging review with a consultant, not from comparing product descriptions.

What the outcomes data actually shows

The headline numbers are close — 70–85% of ChondroFiller-treated patients achieve meaningful symptom relief at three to five years; 70–80% of Arthrosamid patients report significant pain reduction sustained up to five years from a single injection. Treating those figures as equivalent, however, misreads what each trial was actually measuring.

ChondroFiller's published evidence is weighted towards cartilage-specific imaging. MOCART scores — a validated MRI-based measure of repair tissue quality — typically fall between 70 and 87 out of 100 at one year. A 2025 prospective study indexed on PMC, examining ChondroFiller use in intra-articular wrist fractures (25 treated versus controls), found significantly better cartilage quality at follow-up arthroscopy: median Outerbridge scores of 1.5 versus 3.0 (P=0.006) and ICRS scores of 1 versus 3 (P=0.002). These are structural endpoints — changes in the tissue itself, not merely how a patient rates pain on a given day.

Arthrosamid's evidence leans the other way: larger registry cohorts across the knee osteoarthritis population and patient-reported pain outcomes. A 52-week prospective study and a six-month prospective study both confirmed sustained symptom improvement. Of particular note is a 2022 finding by Maulana et al., which documented a reduction in patellofemoral bone marrow lesions following a single Arthrosamid injection — suggesting the hydrogel may exert a structural effect on the subchondral environment beyond its mechanical cushioning role.

Neither product has been tested against the other in a randomised controlled trial, and long-term data beyond five years remains limited for both. That distinction in evidence type has a practical implication: for a patient with a focal cartilage defect, ChondroFiller's imaging endpoints directly address what matters — tissue repair at the bone surface. For diffuse osteoarthritis, Arthrosamid's larger cohort data and the Maulana bone marrow finding are the more relevant reassurance. The strength of the evidence follows the anatomy.

How both injections are given

From a patient's perspective, neither appointment involves surgery, a general anaesthetic, or an overnight stay. Both ChondroFiller® and Arthrosamid® are placed as outpatient injections under local anaesthetic, with ultrasound guidance allowing accurate positioning within the target structure.

For ChondroFiller®, the collagen gel is injected directly over the focal defect site, where it gels in situ within a few minutes to form a scaffold across the damaged surface. The appointment itself is brief; the biological work unfolds gradually over the following months as the patient's own progenitor cells migrate into the scaffold and begin remodelling it. Patients should expect a gradual arc of improvement rather than an immediate shift in symptoms — this is not a quick-relief injection but a regenerative process.

Arthrosamid® follows a similar outpatient format but with a different onset. Once injected, the hydrogel integrates within the synovial lining in roughly a fortnight, requiring no further intervention. Because it is non-degradable and non-resorbable, it remains in place permanently after that initial settling period; re-treatment is not the norm.

In terms of cost, both treatments are broadly comparable at point of entry, with guide costs starting at approximately £3,000 per injection in the UK. ChondroFiller® may run higher where the defect volume is large, since the quantity of scaffold required directly affects the final figure — something confirmed at clinical assessment rather than at initial enquiry.

When both treatments make sense together

Some MRI reports tell a more complicated story: a focal cartilage defect at the load-bearing surface alongside clear signs of synovial inflammation — swelling, thickening, or reactive changes in the joint lining. In that scenario, a single injection addresses only half the picture. Treating the cartilage alone leaves the inflamed synovium unremedied; treating the synovium alone does nothing for the surface defect.

For patients with both findings, the CFI+ protocol delivers ChondroFiller® and Arthrosamid® at a single outpatient appointment. The two injections are placed into their respective anatomical targets — the collagen scaffold over the cartilage defect, the hydrogel into the synovial lining — and each then works through its own mechanism. ChondroFiller® provides the regenerative scaffold component, recruiting the patient's progenitor cells via acellular matrix-induced chondrogenesis. Arthrosamid® provides the synovial cushioning component, integrating sub-synovially within roughly a fortnight. These are not two doses of the same thing; they act on different structures and should not be conflated.

The clinical rationale is sometimes described as 'regenerate and protect': address surface repair and joint-lining inflammation simultaneously, rather than staging two separate visits months apart. UK guide cost for the combined protocol starts at approximately £5,500, confirmed at assessment once imaging has established both targets are present. This is a clinical option when the MRI indicates both — not a routine add-on.

Getting the right diagnosis before choosing

Before either name appears in a consultation, an MRI is needed. Symptom description alone cannot establish whether the primary problem lies at the cartilage surface, within the synovial lining, or both — and that anatomical distinction is what determines which treatment is appropriate. The practical framework the preceding sections set out is straightforward: a focal, well-defined defect in a younger joint points toward ChondroFiller®; diffuse wear with synovial reactivity points toward Arthrosamid®; both findings on the same scan raise the possibility of the CFI+ protocol. Neither product is currently FDA-approved, so patients who have encountered these names through US-based sources should be aware that regulatory status and availability differ.

For patients outside London, MSK Doctors' Sleaford site has an Open MRI scanner and Regeneration Hub, allowing the diagnostic and treatment pathway to be completed in one location. Consultant review can draw on onMRI™, an AI-assisted MRI analysis tool, for objective assessment of cartilage and synovial findings. Appointments do not require a GP referral and are not subject to NHS waiting times; London-based patients can access the same options through the London Cartilage Clinic. A consultation to review existing or new imaging can be arranged at mskdoctors.com — but the meaningful first step is the scan itself, because the scan is what makes the decision answerable.